ImmunoBiochem Corporation

Profile

ImmunoBiochem is a pharma-partnered biotech developing novel degrader-antibody conjugate (DAC) therapeutics for precision immunology. DACs access unique mechanisms via targets on both the surface and inside cells, not accessible to other modalities, with a multi-modal layered logic-gated control of selectivity and potency for precise regulation of immunobiology. ImmunoBiochem's synthetic payloads, designed with controlled targeted protein degradation (TPD) catalytic activity, enable unparalleled in vivo programming of biology. ImmunoBiochem’s lead molecules are addressing autoimmune disorders and various diseases of mucosal immunity.
immunobiochem corporation

Website

immunobiochem.com

Contact


Event details

Date: June 22 - 25, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

23 in total